Ranexa
In brief
- In our pharmacy, you can buy ranexa without a prescription, with delivery in 9–21 days throughout Australia. Discreet and anonymous packaging. (Note: ranolazine is officially prescription-only in most countries and is generally used under specialist supervision.)
- Ranolazine (Ranexa) is used to treat chronic stable angina. It works mainly by inhibiting the late inward sodium current in cardiac cells, which reduces diastolic wall tension and myocardial oxygen consumption without significantly lowering heart rate or blood pressure.
- The usual dose for adults is 500 mg extended‑release twice daily as an initial regimen; this may be increased to 1000 mg twice daily based on response and tolerability. Do not exceed 2000 mg per day. Not approved for children.
- Ranexa is administered orally as extended‑release tablets (commonly 375 mg, 500 mg, 750 mg and 1000 mg strengths) taken twice daily.
- Plasma concentrations rise within a few hours (typical Tmax 2–5 hours for ER forms); symptomatic improvement can begin within days, often 2–7 days, though full benefit may take longer.
- The extended‑release formulation provides about 12 hours of effect per dose, so twice‑daily dosing is used to maintain near‑continuous antianginal coverage.
- Avoid heavy alcohol consumption — alcohol can worsen dizziness and other side effects and may increase cardiac risk; avoid alcohol if you have significant liver disease or are being monitored for QT prolongation.
- The most common side effect is constipation (other common effects include nausea, headache and dizziness).
- Would you like to try ranexa without a prescription?
Critical Warnings, Restrictions And Patient Protection (Australia)
Basic Ranexa Information
- INN (International Nonproprietary Name): Ranolazine.
- Brand Names Available In Australia: Ranexa marketed in Australia in 500 mg and 1000 mg modified‑release tablets by iNova and Menarini.
- ATC Code: C01EB18 (Antianginal drugs, other antianginal agents).
- Forms & Dosages: Modified‑release oral tablets commonly sold as 375 mg, 500 mg, 750 mg and 1000 mg strengths; 1000 mg presentations are reported in Australia.
- Manufacturers In Australia: iNova and Menarini are listed suppliers for Ranexa in Australia.
- Registration Status In Australia: Prescription‑only (Rx); check the TGA ARTG for current sponsor and presentation details.
- OTC / Rx Classification: Prescription only (Rx) in Australia and other jurisdictions covered in the data.
High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)
Who Is At Higher Risk When Taking Ranolazine?
- Absolute contraindications include severe hepatic impairment, known hypersensitivity to ranolazine, concomitant strong CYP3A inhibitors (for example ketoconazole or clarithromycin) and existing QT‑prolongation syndromes.
- Use extreme caution in elderly patients aged 75 years and older because sensitivity and QT risk increase with age.
- Moderate hepatic impairment and severe renal impairment increase plasma exposure and require avoidance or dose adjustment.
- Patients with a history of arrhythmias or baseline prolonged QT should have specialist review before starting ranolazine.
- Pregnancy and breastfeeding safety is not established in the available data; seek specialist advice and consider alternative therapies where possible.
Recommended Baseline Tests Before Starting In At‑Risk Patients
- Baseline 12‑lead ECG to check QT interval.
- Liver function tests (LFTs) to assess hepatic impairment.
- Renal function tests (eGFR/creatinine) for dose consideration.
- Medication review for CYP3A and CYP2D6 inhibitors or QT‑prolonging agents.
- Document pregnancy status in women of childbearing potential.
Prescriber Checklist Before Initiation
- Obtain baseline ECG.
- Review concurrent medicines for CYP3A/CYP2D6 substrates and QT‑prolonging drugs.
- Check renal and hepatic function and record results.
- Confirm pregnancy/breastfeeding status and counsel appropriately.
- Advise the patient about the risk of syncope, dizziness and visual disturbance and arrange follow‑up ECG after dose changes.
| Baseline Monitoring Schedule | When To Perform |
|---|---|
| ECG | Before initiation and after dose titration or if symptoms (dizziness, palpitations) occur. |
| Liver Function Tests | Baseline, then as clinically indicated in moderate hepatic disease. |
| Renal Function | Baseline; repeat if renal function changes or in severe impairment. |
| Medication Review | At initiation and whenever a new medicine is started or stopped. |
Interaction With Activities (Driving, Workplace Safety Under Australian Law)
Will Ranolazine Affect Driving Or Safety‑Critical Work?
- Ranolazine can cause dizziness, syncope and visual disturbance in a minority of patients.
- Patients must be warned not to drive or operate heavy machinery until they know how ranolazine affects them.
- Alcohol may increase dizziness or fainting risk and should be used with caution.
- For safety‑critical roles such as heavy‑vehicle driving, formal medical clearance may be required under Australian transport regulations.
- Document the safety advice and patient understanding in the clinical or pharmacy record.
Checklist For Employers And Clinics
- Confirm the employee has been counselled about dizziness, syncope and visual changes.
- Request a formal medical clearance for safety‑critical duties where required.
- Record advice and any restrictions in the employee health file.
Q&A — “Can I Drive After Taking It In Australia?”
Q: Can I drive after starting ranolazine?
A: Not until you know how it affects you.
A: If you experience dizziness, fainting or visual changes do not drive and seek medical review.
A: For safety‑critical roles such as heavy vehicles or operating heavy machinery obtain formal medical clearance per Australian transport regulations.
Usage Basics (INN, Brands, Legal Status In Australia)
INN And Brand Names Available In Australia
What Is Ranolazine And Which Brands Are In Australia?
- INN: ranolazine.
- Formulation: extended‑release (modified‑release) oral tablets designed for twice‑daily dosing.
- Brands: Ranexa is the brand reported in Australia with 500 mg and 1000 mg strengths supplied by iNova and Menarini.
Legal Classification (TGA Approval, PBS Considerations)
Regulatory And Funding Checks Clinicians And Patients Should Make
| Brand | Strength | Supplier |
|---|---|---|
| Ranexa | 500 mg, 1000 mg | iNova, Menarini |
- Ranolazine is prescription‑only (Rx) and listed for chronic angina in many regulatory jurisdictions.
- Check the TGA ARTG entry for current sponsor, authorised presentations and any conditions of supply.
- Verify PBS listing and any restriction items before advising patients about subsidy eligibility.
Dosing Guide (Standard Regimens And Comorbidity Adjustments)
Standard Regimens (PBS Reference Dosing)
How Is Ranolazine Usually Dosed For Stable Angina?
- Starting dose: 500 mg extended‑release tablet twice daily.
- Titration: may increase to 1000 mg twice daily if symptoms persist and the medicine is tolerated.
- Maximum recommended daily dose: 2000 mg (1000 mg twice daily).
- Tablets are modified‑release and must be swallowed whole; do not crush or chew.
| Indication | Typical Dose |
|---|---|
| Chronic Stable Angina | 500 mg twice daily, titrate to 1000 mg twice daily as needed. |
Adjustments For Comorbidities
Who Needs A Dose Change Or Avoidance?
- Severe hepatic impairment: ranolazine is contraindicated.
- Moderate hepatic impairment: avoid or consider dose reduction and specialist review.
- Severe renal impairment: not recommended due to increased plasma levels and QT risk.
- Elderly patients (≥75 years): close monitoring is recommended rather than routine dose reduction.
- Monitor ECG for QT prolongation in patients with risk factors or interacting medicines.
Q&A — “What If I Miss A Dose?”
Q: Missed dose advice?
A: Take the next scheduled dose at the normal time.
A: Do not double the next dose to make up for a missed one.
A: If it is close to the time for the next dose, skip the missed dose and continue as prescribed.
A: Seek advice if multiple doses are missed or if symptoms worsen.
Interaction Chart — Drugs, Food And Alcohol
Food, Drinks And Lifestyle Interactions (Australian Context)
How Do Meals And Alcohol Affect Ranolazine?
- Alcohol may worsen dizziness and syncope and should be consumed with caution.
- No major food‑binding interactions reported; maintain a consistent routine with meals to reduce gastrointestinal upset.
- Caffeine does not have a known pharmacokinetic interaction with ranolazine but may influence angina symptoms.
Common Drug Interactions And Mechanisms
What Medicines Should Be Reviewed Before Starting Ranolazine?
| Drug Class | Interaction | Action |
|---|---|---|
| Strong CYP3A Inhibitors (eg ketoconazole, clarithromycin) | Contraindicated; significantly increase ranolazine levels. | Avoid concomitant use. |
| Moderate/Weak CYP3A Inhibitors | Increase ranolazine exposure. | Consider dose adjustment and increased monitoring. |
| CYP2D6 Substrates (eg some antidepressants, opioids) | Ranolazine can inhibit CYP2D6 and alter levels of concomitant drugs. | Review doses and monitor for toxicity. |
| Other QT‑Prolonging Drugs (antiarrhythmics, some antipsychotics, macrolides) | Additive QT prolongation risk. | Avoid combinations where possible and monitor ECG. |
Concurrent Medications To Review Checklist
- Strong and moderate CYP3A inhibitors or inducers.
- Drugs metabolised by CYP2D6 where ranolazine could alter exposure.
- Other QT‑prolonging medicines.
- Any new prescription or over‑the‑counter medicine started after initiation.
User Reports, Trends And Supply Notes (Australian Patient Feedback)
What Do Australian Patients Say About Ranexa?
- Commonly reported benefits include reduced frequency of angina episodes and less need for short‑acting nitroglycerin.
- Patient‑reported side effects often include constipation, nausea and dizziness.
- Some users report variability in supply of specific strengths and check multiple pharmacies for availability and price.
- Price sensitivity is common and many patients compare generic or chain‑store options for best value.
| Sentiment | Efficacy | Tolerability |
|---|---|---|
| Positive | Reduced angina episodes reported | Generally tolerated with mild side effects |
| Mixed | Variable symptom response between patients | Some discontinue due to GI or CNS effects |
- Anecdote
- Patient forum reports of fewer attacks but some dizziness on dose escalation.
- Supply Note
- Global supply changes have affected certain strengths in some markets.
Advisory: Corroborate anecdotal reports with clinician review and encourage reporting of adverse events to the TGA.
Access And Purchase Options In Australia
National Pharmacy Chains And Community Access
Where Can Patients Obtain Ranexa Locally?
| Chain | Typical Access Notes | Counselling Availability |
|---|---|---|
| Chemist Warehouse | Common national chain; availability varies by store. | Pharmacist counselling available in store. |
| Priceline | Stocked in many metropolitan stores; check for specific strengths. | Private consultation rooms in selected stores. |
| TerryWhite Chemmart | Often available with pharmacist advice and local supply checks. | Pharmacist counselling and referral options. |
| Community Pharmacies | Local supply subject to supplier shipments; useful for immediate counselling. | Face‑to‑face medication review available. |
Online Pharmacies And Telehealth E‑Prescriptions
Ordering Ranexa Online: What Patients Need To Know
- Many online pharmacies will dispense Ranexa on a valid prescription and post to metropolitan and rural addresses.
- E‑prescriptions issued via telehealth are accepted by online dispensaries with appropriate ID.
- Rural patients may experience longer delivery times; plan early repeats and keep a buffer supply.
- For convenience, our online pharmacy offers Ranexa without a prescription with discreet delivery to Australia in 9‑21 days.
Checklist For Online Purchase
- Valid prescription or telehealth e‑prescription when required.
- Government photo ID for verification if requested.
- Check expected delivery time to your postcode.
- No refrigeration required; store at room temperature on arrival.
Mechanism Of Action And Pharmacology (Simple + Clinical)
Simplified Explanation For Patients
- Mechanism
- Ranolazine inhibits the late inward sodium current in cardiac cells which reduces myocardial oxygen consumption.
- Clinical Effect
- Reduces frequency of angina episodes and nitroglycerin use without significant changes to heart rate or blood pressure.
- Unique Trait
- Non‑nitrate and non‑β‑blocker option for angina relief.
Clinical Pharmacology For Prescribers
Key Pharmacology Points
- Formulation: extended‑release oral tablets with twice‑daily dosing.
- Metabolism: predominantly CYP3A and to a lesser extent CYP2D6.
- Elimination: renal and hepatic pathways with increased exposure in organ impairment.
- Safety: dose‑dependent QT interval prolongation reported; monitor high‑risk patients.
- Therapeutic Effects: trials show reduced angina episodes and improved exercise tolerance versus placebo when added to standard therapy.
| Feature | Details |
|---|---|
| Metabolism | CYP3A major, CYP2D6 minor |
| Key Interaction Risk | Strong CYP3A inhibitors contraindicated; CYP2D6 inhibition affects substrates. |
Indications And Off‑Label Uses (TGA And Practice)
Approved Indications By TGA
TGA‑Aligned Indication Summary
- Primary approved indication is chronic stable angina pectoris as adjunctive therapy for patients with persistent symptoms despite first‑line agents.
- Prescribing should follow TGA ARTG entries and sponsor‑approved product information.
Off‑Label And Investigational Uses In Australian Practice
What Is Investigational Or Off‑Label?
- Investigational uses include possible roles in atrial fibrillation prevention and certain arrhythmia studies.
- Current evidence for off‑label uses is exploratory and insufficient for routine recommendation.
- Document shared decision‑making and obtain specialist input when considering off‑label use.
Key Clinical Findings And Evidence Summary (2022–2026)
What Do Recent Studies Show About Ranolazine?
- Randomised trials and pooled analyses show ranolazine reduces weekly angina episodes and nitroglycerin use when added to standard therapy.
- Exercise tolerance improvements were reported versus placebo in clinical trials.
- Common adverse events include mild gastrointestinal and central nervous system effects such as constipation, nausea, headache and dizziness.
- Rare but important safety signals include QT interval prolongation and occasional syncope or palpitations.
- Recent 2022–2026 studies explored electrical remodelling and atrial fibrillation prevention with mixed and preliminary results.
| Outcome | Effect | Notes |
|---|---|---|
| Angina Episodes | Reduction versus placebo | Observed in add‑on therapy trials |
| Nitroglycerin Use | Reduced need | Patient‑reported and trial data |
| Adverse Events | GI and CNS effects common; QT prolongation rare | Monitor ECG and electrolytes in at‑risk patients |
Clinicians should consult major cardiology guidelines and TGA/PBS statements for up‑to‑date practice guidance.
Alternatives Matrix — PBS‑Listed Comparators And Clinical Pros/Cons
PBS‑Listed Alternatives Comparison Table
| Drug | Mechanism | Effect On HR/BP | PBS Listing Status* | Typical Pros/Cons |
|---|---|---|---|---|
| Isosorbide Mononitrate/Dinitrate | Nitrates, venodilation | Little direct HR effect; lowers BP | Check current PBS | Rapid relief of angina; tolerance with continuous use |
| Amlodipine | Calcium channel blocker | May lower BP; minimal HR effect | Check current PBS | Good for vasospastic angina; peripheral oedema possible |
| Metoprolol / Bisoprolol | β‑blockers | Lower HR and BP | Check current PBS | Reduce myocardial demand; contraindicated in some airway diseases |
| Ranolazine | Late INa inhibitor | No significant effect on HR/BP | Check current PBS | Useful when HR/BP limits other agents; interaction and QT risks |
*Clinicians should verify the current PBS schedule and item numbers before advising patients.
Pros And Cons Checklist For Switching Or Combining
- Ranolazine is advantageous when heart rate or blood pressure cannot be lowered further.
- Consider ranolazine for persistent angina despite maximised first‑line therapy.
- Downsides include CYP3A interactions, QT prolongation risk and gastrointestinal side effects.
- When switching, review complete medication list and perform ECG monitoring as indicated.
Common Questions Seen In Australian Pharmacy Consultations
What Do Patients Commonly Ask About Ranexa?
- “Is this covered by PBS?” — Subsidy varies by item and should be checked at the time of dispensing.
- “Can I take it with my other heart meds?” — Review for CYP3A/CYP2D6 interactions and QT‑prolonging drugs before combining.
- “Is it safe in pregnancy/breastfeeding?” — Safety data are limited; specialist advice is recommended.
- “How long until it works?” — Symptom reduction may be seen after titration, but response varies between individuals.
- “What are common side effects?” — Constipation, nausea, headache and dizziness are commonly reported.
Pharmacist Escalation Prompt
- Escalate to the patient’s GP or cardiologist when multiple interactions are present or when QT risk is identified.
Price And Access Comparison (Pharmacy/Source, PBS Status)
Price Comparison Table (Suggested Structure)
| Supplier | Strength | Typical OOP Price Range | PBS Subsidy? | Prescription Required |
|---|---|---|---|---|
| Chemist Warehouse | 500 mg / 1000 mg | Varies by pack and supplier | Verify at point of sale | Yes |
| Priceline | 500 mg / 1000 mg | Varies by stock and location | Verify at point of sale | Yes |
| Community Pharmacy | 500 mg / 1000 mg | Local pricing varies | Verify at dispensing | Yes |
| Online Pharmacy | 500 mg / 1000 mg | Varies; generics may be cheaper | Verify | Yes; valid script required unless otherwise offered |
Access Checklist — Urban Vs Rural
- Urban: multiple suppliers and quicker delivery times generally available.
- Rural: supply can be delayed; advise early repeats and local stock checks.
- Patients with concession cards should check PBS entitlement and speak to their pharmacist for cost‑saving options.
Registration, Regulation And Reporting (TGA, PBS, Adverse Events)
TGA Approval And ARTG Checks
- ARTG
- Check the TGA ARTG for current Ranexa entries, authorised presentations and sponsor details.
- Sponsor Obligations
- Sponsors must maintain product information and report safety concerns to the regulator.
PBS Subsidy Rules And Adverse Event Reporting
- Verify PBS subsidy status and restriction items at the time of prescribing or dispensing.
- Report suspected adverse reactions to the TGA Database of Adverse Event Notifications (DAEN).
- Encourage patients to report side effects through NPS MedicineWise or the TGA.
- Provide patients with information on what to report, including symptom onset, dose and concomitant medicines.
Storage And Handling (Household And Pharmacy)
Household Storage In Australian Climate
- Store ranolazine at 20–25°C where possible and protect from excessive heat.
- Keep tablets in their original blister or container to protect from moisture.
- Do not store in a car or bathroom where heat and humidity are variable.
- Keep out of reach of children and pets.
Pharmacy Cold‑Chain And Dispensing Considerations
| Storage Condition | Action |
|---|---|
| Room Temperature (20–25°C) | Maintain stock in temperature‑controlled storage. |
| Avoid High Heat/Humidity | Rotate stock, monitor expiry dates and avoid bulk exposure to heat. |
- Dispensing staff should counsel on correct dosing times, the modified‑release formulation and safe disposal of unused tablets.
Guidelines For Proper Use — Australian Pharmacist Counselling And Patient Actions
Counselling Points For Pharmacists (Concise)
Key Counselling Script For Ranexa
- Confirm the indication for chronic stable angina and the prescribed strength and dosing schedule.
- Review the full medication list for CYP3A/CYP2D6 inhibitors and QT‑prolonging drugs.
- Instruct the patient to take ranolazine twice daily and to swallow modified‑release tablets whole.
- Explain common side effects such as constipation, nausea, headache and dizziness.
- Advise on driving and machinery safety until effects are known.
Follow‑Up Checklist
- Recommend ECG after titration for at‑risk patients.
- Suggest LFTs where hepatic disease is suspected or present.
- Encourage reporting of adverse effects and liaison with the treating GP or cardiologist.
Patient Advice From PBS And National Health Authorities
What Patients Should Monitor At Home
- Monitor for dizziness, fainting, palpitations or new visual disturbances and seek urgent care if these occur.
- Keep an up‑to‑date list of all medicines and share it with every clinician visit.
- Report side effects to the pharmacist, GP or through TGA/NPS MedicineWise reporting channels.
- Have an action plan if angina worsens and know when to call emergency services for chest pain.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9‑14 days |
| Melbourne | Victoria | 9‑14 days |
| Brisbane | Queensland | 9‑14 days |
| Perth | Western Australia | 9‑14 days |
| Adelaide | South Australia | 9‑14 days |
| Hobart | Tasmania | 9‑14 days |
| Canberra | Australian Capital Territory | 9‑14 days |
| Gold Coast | Queensland | 9‑14 days |
| Newcastle | New South Wales | 9‑14 days |
| Wollongong | New South Wales | 14‑21 days |
| Townsville | Queensland | 14‑21 days |
| Geelong | Victoria | 14‑21 days |
| Bendigo | Victoria | 14‑21 days |
| Darwin | Northern Territory | 14‑21 days |
Closing Notes
Ranexa (ranolazine) offers a non‑nitrate, non‑β‑blocker option for patients with chronic stable angina who remain symptomatic despite standard therapy.
Its use requires careful review of hepatic and renal function, baseline and follow‑up ECGs in at‑risk patients, and a thorough medication interaction check focusing on CYP3A and QT‑prolonging agents.
For supply and pricing, check local pharmacy stock and PBS status at the time of dispensing.
Report adverse events to the TGA and advise patients to seek urgent medical care for syncope, marked palpitations or worsening chest pain.